Palvella Therapeutics PVLA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$15.77M-24.0% | -$12.71M-12.1% | -$11.35M-19.8% | -$9.47M-15.7% | -$8.19M-35.0% | ||
| $3.38M+62.0% | $2.08M+16.4% | $1.79M+24.9% | $1.43M+31.0% | $1.09M+308% | ||
| -$10.86M-121% | -$4.93M+37.5% | -$7.88M-45.0% | -$5.43M+19.7% | -$6.77M-25.5% | ||
| -$55.44M— | —— | —— | —— | $0— | ||
| $214.73M+438,327% | -$49K— | —— | —— | -$1.2M-102% | ||
| $148.41M+2,757% | -$5.59M+18.7% | -$6.87M-32.2% | -$5.19M+34.9% | -$7.98M-111% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Palvella Therapeutics generate?
- Palvella Therapeutics (PVLA) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Palvella Therapeutics's free cash flow?
- Palvella Therapeutics's free cash flow was -$15.2M over the trailing twelve months, up 67.1% year over year.
- Where does Palvella Therapeutics's cash flow data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
